An in situ depot for the sustained release of a TLR7/8 agonist in combination with a TGFβ inhibitor promotes anti-tumor immune responses.

Autor: Jensen SB; Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark., Jæhger DE; Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark., Serrano-Chávez E; Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark., Halldórsdóttir HR; Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark., Engel TB; Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark., Jørgensen JS; Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark., Björgvinsdóttir UJ; Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark., Kostrikov S; Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark., Scheeper MJ; Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark., Ringgaard L; Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark., Bruun LM; Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark., Stavnsbjerg C; Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark., Christensen E; Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark., Bak M; Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark., Thuroczy J; Animal Health Center Budafok, Budapest, Hungary., Balogh L; Animal Health Center Budafok, Budapest, Hungary., Jensen ATI; Department of Health Technology, Center for Nanomedicine and Theranostics, Technical University of Denmark, Roskilde, Denmark., Melander F; Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark., Kjaer A; Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital, Copenhagen, Denmark.; Cluster for Molecular Imaging, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark., Henriksen JR; Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark., Hansen AE; Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark., Andresen TL; Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark. tlan@dtu.dk.

Publikováno v: Nature communications [Nat Commun] 2024 Sep 03; Vol. 15 (1), pp. 7687. Date of Electronic Publication: 2024 Sep 03.

Matrix effect in tumor lysates - Does it affect your cytokine ELISA and multiplex analyses?

Autor: Stavnsbjerg C; Department of Health Technology, Section for Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kongens Lyngby, Denmark., Jørgensen JS; Department of Health Technology, Section for Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kongens Lyngby, Denmark., Engel TB; Department of Health Technology, Section for Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kongens Lyngby, Denmark., Brus A; Department of Health Technology, Section for Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kongens Lyngby, Denmark., Ringgaard L; Department of Health Technology, Section for Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kongens Lyngby, Denmark., Hansen AE; Department of Health Technology, Section for Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kongens Lyngby, Denmark., Kjaer A; Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark., Andresen TL; Department of Health Technology, Section for Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kongens Lyngby, Denmark. Electronic address: tlan@dtu.dk.

Publikováno v: Journal of immunological methods [J Immunol Methods] 2022 Jan; Vol. 500, pp. 113177. Date of Electronic Publication: 2021 Oct 28.

Tumor repolarization by an advanced liposomal drug delivery system provides a potent new approach for chemo-immunotherapy.

Autor: Ringgaard L; Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark., Melander F; Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark., Eliasen R; Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark., Henriksen JR; Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark., Jølck RI; Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark., Engel TB; Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark., Bak M; Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark., Fliedner FP; Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark., Kristensen K; Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark., Elema DR; The Hevesy Laboratory, Center for Nuclear Technologies, Technical University of Denmark, Roskilde, Denmark., Kjaer A; Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark., Hansen AE; Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark., Andresen TL; Department of Health Technology, Biotherapeutic Engineering and Drug Targeting, Technical University of Denmark, Kgs. Lyngby, Denmark. tlan@dtu.dk.

Publikováno v: Science advances [Sci Adv] 2020 Sep 04; Vol. 6 (36). Date of Electronic Publication: 2020 Sep 04 (Print Publication: 2020).

The hard protein corona of stealth liposomes is sparse.

Autor: Kristensen K; Department of Health Technology, DTU Health Tech, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark; Center for Nanomedicine and Theranostics, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark. Electronic address: kakri@dtu.dk., Engel TB; Department of Health Technology, DTU Health Tech, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark; Center for Nanomedicine and Theranostics, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark., Stensballe A; Department of Health Science and Technology, Aalborg University, 9220 Aalborg Ø, Denmark., Simonsen JB; Department of Health Technology, DTU Health Tech, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark; Center for Nanomedicine and Theranostics, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark., Andresen TL; Department of Health Technology, DTU Health Tech, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark; Center for Nanomedicine and Theranostics, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark. Electronic address: tlan@dtu.dk.

Publikováno v: Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2019 Aug 10; Vol. 307, pp. 1-15. Date of Electronic Publication: 2019 Jun 03.